The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Structure/function of α‐synuclein in health and disease: rational development of animal models for Parkinson's and related diseases
Abstract
α-Synuclein (αSYN) was originally identified in the electric organ of the electric eel Torpedo californica ( Maroteaux et al. 1988 ). It is now well documented that αSYN and its close homolog βSYN are abundantly expressed in presynaptic terminals of vertebrates. Experimental down-regulation of αSYN in knock-out mice and in primary neurones suggests that αSYN regulates synaptic neurotransmission, but the molecular mechanism is still poorly understood. A breakthrough was achieved when two different mutations in the αSYN gene were identified in autosomal-dominant hereditary Parkinson's disease (PD) patients. Soon thereafter, αSYN was found to be the major protein component in the hallmark lesions of PD [Lewy bodies (LBs) and Lewy neurites]. Lewy pathology is also characteristic for dementia with LBs (DLB), the LB variant of Alzheimer's disease, and neurodegeneration with brain iron accumulation type 1 (formerly known as Hallervorden–Spatz disease). Moreover, αSYN fibrils are deposited in (oligodendro)glial cytoplasmic inclusions (GCIs) of multiple system atrophy (MSA) patients. α-Synuclein specifically has an intrinsic propensity to form fibrils in vitro. PD-associated mutations and oxidative stress enhance αSYN aggregation. During fibril formation, the naturally unfolded αSYN undergoes conformational changes, transiently existing as a partially folded intermediate and protofibril. It is a matter of intense research to establish whether the folding intermediates and/or the LB fibrils exert neurotoxicity in human patients. To better understand the pathophysiology of αSYN, a number of transgenic animal models have been developed. Expression of human αSYN in Drosophila melanogaster caused age-dependent, dopamine-selective neurodegeneration and the formation of LB-like deposits. A variety of promoters have been used to express transgenic αSYN in mice. Aberrant accumulation of αSYN in cell bodies and swollen neurites were common observations. Some models displayed age-dependent enhancement of phenotype, such as formation of ubiquitin-positive inclusions, loss of dopaminergic synapses and locomotor deficits. Of great relevance are recent reports that amyloid seeded αSYN aggregation, whereas the non-amyloidogenic βSYN inhibited αSYN fibril formation both in vitro and in vivo. Still, additional genetic and/or environmental risk factors need to be considered in order to generate a complete mouse model of PD. The synucleins comprise a family of 15–20-kDa proteins including αSYN, βSYN and γSYN (also termed persyn) (Kahle et al. 2000a). The primary sequences span three regions (Fig. 1a). The amino-terminal half is characterized by five or six imperfectly conserved repeats (EKTKEGV, single-letter code). This region acquires α-helical secondary structure upon lipid binding (Eliezer et al. 2001), whereas the less conserved carboxy-terminus, in which acidic amino acid side chains are clustered, is highly flexible (Eliezer et al. 2001). A stretch of amino acids critically involved in αSYN aggregation (Giasson et al. 2001; Kahle et al. 2001) resides in the central, hydrophobic portion (called non-amyloid component [NAC]). (a) Schematic representation of synucleins. The imperfect KTKEGV repeats are numbered, the 6th repeat missing in βSYN is stippled. (b and c) Kyte–Doolittle hydropathy plots of αSYN (b) and βSYN (c). The NAC domain amino acid sequences are aligned in the middle, and are indicated by black boxes under each hydropathy plot. The natural deletion in βSYN is stippled. (dand e) Cortical LBs in the temporal cortex (arrows) in a DLB case showing strong αSYN immunoreactivity (d), but no labeling for βSYN (e). The absence of βSYN immunoreactivity in an LB (arrow) displacing a neuronal nucleus (arrowhead) is featured in the insert. The amino-terminal repeats of αSYN were predicted to form an α-helical structure similar to the lipid-binding domains of class A2 apolipoproteins (Davidson et al. 1998). Indeed, αSYN tightly binds to synthetic phospholipid vesicles, and preferentially binds to those with acidic head groups (Davidson et al. 1998; Jo et al. 2000). Mutational analysis of lipid-binding determinants (Perrin et al. 2000) revealed that the lipid-binding domain was broadly distributed over the amino-terminal half of αSYN. Amphipathic class A2 helix formation was crucial because replacement of the six amino-terminal threonines (predicted to lie along the hydrophobic face of the helix) with charged amino acids disrupted binding of mutant αSYN with vesicles. Recombinant full-length, but not amino-terminally truncated αSYN interacted with a crude membrane fraction from rat brain (Jensen et al. 1998). Both PD-associated mutations (A53T, Polymeropoulos et al. 1997; A30P, Krüger et al. 1998) reside in the lipid-binding amino-terminus of αSYN (Fig. 1a). The A30P mutation abolishes a helical moment in the amino-terminus (Bussell and Eliezer 2001), and was reported to disrupt αSYN binding to rat brain membranes (Jensen et al. 19
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, the protein α-synuclein, which aggregates into Lewy bodies in Parkinson’s disease43, 44, has a lower predicted propensity for granule formation when compared to Tau, but could still undergo liquid–liquid demixing according to the catGranule score (Fig. 1c).”
From Liquid–liquid phase separation of the microtubule-binding repeats of the Alzheimer-related protein Tau (2017) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
Evidence for a Partially Folded Intermediate in α-Synuclein Fibril Formation
Uversky, V. N., Li, J., & Fink, A. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010907200 · Cited by 1,096
Giasson, B. I., Murray, I. V. J., Trojanowski, J. Q., & Lee, V. M.-Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008919200 · Cited by 1,080
Lee, M. K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A. S., Dawson, T. M., Copeland, N. G., Jenkins, N. A., & Price, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132197599 · Cited by 824
Tu, P., Galvin, J. E., Baba, M., Giasson, B., Tomita, T., Leight, S., Nakajo, S., Iwatsubo, T., Trojanowski, J. Q., & Lee, V. M. ‐. (1998) · Annals of Neurology · doi:10.1002/ana.410440324 · Cited by 686 · cited 1×
“Finally, aSYN was identified as the building block of the GCIs that characterize MSA (Gai et al. 1998; Tu et al. 1998; Wakabayashi et al. 1998).”
BackgroundProteasomal function is impaired in substantia nigra in Parkinson’s disease
McNaught, K. S. P., & Jenner, P. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01701-8 · Cited by 653
α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy
Wakabayashi, K., Yoshimoto, M., Tsuji, S., & Takahashi, H. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00407-8 · Cited by 643
Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., & Mucke, L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211412398 · Cited by 607
Lippa, C. F., Fujiwara, H., Mann, D. M. A., Giasson, B., Baba, M., Schmidt, M. L., Nee, L. E., O'Connell, B., Pollen, D. A., St. George-Hyslop, P., et al. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65722-7 · Cited by 533
Degradation of α-Synuclein by Proteasome
Bennett, M. C., Bishop, J. F., Leng, Y., Chock, P. B., Chase, T. N., & Mouradian, M. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.48.33855 · Cited by 417
Research works printed but not linked: 84
- 10.1016/S0304-3940(00)01049-1 · DOI
- 10.1016/S0304-3940(00)01623-2 · DOI
- 10.1212/WNL.51.3.887 · DOI · Paper page
- Baba M., 1998, Aggregation of α‐synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies, Am. J. Pathol., 152, 879
- 10.1016/S0304-3940(99)00311-0 · DOI
- 10.1126/science.292.5521.1552 · DOI · Paper page
- 10.1038/81834 · DOI · Paper page
- 10.1074/jbc.M106777200 · DOI · Paper page
- CampbellB. C. LiQ.‐X. CulvenorJ. G. JäkäläP. CappaiR. BeyreutherK. MastersC. L.andMcLeanC. A.(2000) Accumulation of insoluble α‐synuclein in dementia with Lewy bodies.Neurobiol. Dis.7 192–200. · DOI
- 10.1038/3311 · DOI · Paper page
- 10.1021/bi991447r · DOI · Paper page
- 10.1073/pnas.97.2.571 · DOI · Paper page
- 10.1126/science.1063522 · DOI · Paper page
- 10.1016/S0002-9440(10)65220-0 · DOI · Paper page
- 10.1074/jbc.273.16.9443 · DOI · Paper page
- 10.1006/jmbi.2001.4538 · DOI · Paper page
- 10.1038/35006074 · DOI · Paper page
- Fujiwara H., 2002, α‐Synuclein is phosphorylated in synucleinopathy lesions, Nat. Cell. Biol, 4, 160–164, 10.1038/ncb748 · DOI · Paper page
- 10.1016/S0140-6736(05)79256-4 · DOI · Paper page
- 10.1016/S0002-9440(10)64548-8 · DOI · Paper page
- 10.1016/0896-6273(95)90040-3 · DOI · Paper page
- 10.1007/BF01291788 · DOI · Paper page
- 10.1046/j.1471-4159.2000.0752221.x · DOI
- 10.1074/jbc.274.12.7619 · DOI · Paper page
- 10.1126/science.290.5493.985 · DOI · Paper page
- 10.1016/S0896-6273(02)00682-7 · DOI · Paper page
- 10.1016/S0959-437X(00)00200-8 · DOI
- 10.1016/S0006-8993(98)00514-9 · DOI · Paper page
- 10.1097/00001756-199903170-00011 · DOI · Paper page
- 10.1074/jbc.274.41.28849 · DOI · Paper page
- 10.1146/annurev.biochem.67.1.425 · DOI · Paper page
- 10.1212/WNL.54.10.1916 · DOI · Paper page
- 10.1083/jcb.96.5.1374 · DOI · Paper page
- 10.1097/00005072-199804000-00005 · DOI · Paper page
- 10.1074/jbc.273.41.26292 · DOI · Paper page
- 10.1074/jbc.M004345200 · DOI · Paper page
- 10.1111/j.1749-6632.2000.tb06902.x · DOI
- 10.1523/JNEUROSCI.20-17-06365.2000 · DOI · Paper page
- 10.1016/S0002-9440(10)63072-6 · DOI · Paper page
- 10.1212/WNL.56.7.980 · DOI
- 10.1021/bi001441y · DOI
- 10.1097/00001756-200001170-00041 · DOI · Paper page
- 10.1038/ng0298-106 · DOI · Paper page
- 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F · DOI
- 10.1096/fsb2fj000334com · doi:10.1096/fsb2fj000334com · Paper page
- 10.1074/jbc.M105326200 · DOI · Paper page
- 10.1021/bi010616g · DOI · Paper page
- 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4 · doi:10.1002/1531-8249(199903)45:3<353::aid-ana11>3.0.co;2-4
- 10.1523/JNEUROSCI.08-08-02804.1988 · DOI · Paper page
- 10.1126/science.287.5456.1265 · DOI · Paper page
- 10.1007/s004019900168 · DOI · Paper page
- 10.1074/jbc.275.12.8812 · DOI · Paper page
- 10.1523/JNEUROSCI.20-09-03214.2000 · DOI · Paper page
- 10.1111/j.1432-1033.1993.tb18337.x · DOI · Paper page
- 10.1021/bi002952n · DOI · Paper page
- 10.1074/jbc.274.14.9843 · DOI · Paper page
- 10.1074/jbc.275.1.390 · DOI · Paper page
- 10.1074/jbc.M004851200 · DOI · Paper page
- 10.1126/science.276.5321.2045 · DOI · Paper page
- 10.1074/jbc.M003542200 · DOI · Paper page
- 10.1523/JNEUROSCI.20-16-06021.2000 · DOI · Paper page
- 10.1046/j.1471-4159.2001.00474.x · DOI · Paper page
- 10.1016/S0006-8993(01)02772-X · DOI · Paper page
- 10.1073/pnas.97.9.4897 · DOI · Paper page
- Sharma N., 2001, Alpha‐synuclein has an altered conformation and shows a tight intermolecular interaction with ubiquitin in Lewy bodies, Acta Neuropathol., 102, 329, 10.1007/s004010100369 · DOI
- 10.1016/0006-8993(93)90796-P · DOI
- 10.1074/jbc.M000206200 · DOI · Paper page
- 10.1016/S0304-3940(98)00504-7 · DOI · Paper page
- 10.1073/pnas.95.11.6469 · DOI · Paper page
- 10.1038/42166 · DOI · Paper page
- Takeda A., 1998, Abnormal accumulation of NACP/α‐synuclein in neurodegenerative disorders, Am. J. Pathol., 152, 367
- 10.1016/S0014-5793(01)03115-5 · DOI · Paper page
- 10.1073/pnas.90.23.11282 · DOI · Paper page
- 10.1074/jbc.M105343200 · DOI · Paper page
- 10.1016/S0014-5793(01)02597-2 · DOI · Paper page
- 10.1046/j.1471-4159.2000.740721.x · DOI · Paper page
- 10.1021/bi0102398 · DOI · Paper page
- 10.1016/S0304-3940(97)00891-4 · DOI · Paper page
- 10.1046/j.1365-2990.1999.00193.x · DOI
- 10.1021/bi961799n · DOI · Paper page
- 10.1097/00001756-200011270-00029 · DOI
- 10.1016/S0165-3806(96)00210-6 · DOI · Paper page
- 10.1074/jbc.274.28.19509 · DOI · Paper page
- 10.1016/S0006-8993(99)02207-6 · DOI
Cited by
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Self-citationα-Synuclein Is Degraded by Both Autophagy and the Proteasome
Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300227200 · Cited by 1,429
Structure and Dynamics of Micelle-bound Human α-Synuclein
Ulmer, T. S., Bax, A., Cole, N. B., & Nussbaum, R. L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411805200 · Cited by 966
Ambadipudi, S., Biernat, J., Riedel, D., Mandelkow, E., & Zweckstetter, M. (2017) · Nature Communications · doi:10.1038/s41467-017-00480-0 · Cited by 782
Metadata
- Authors
- Kahle, P. J., Haass, C., Kretzschmar, H. A., & Neumann, M.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2002-07-24
- Volume
- 82
- Issue
- 3
- Pages
- 449-457
- ISSN
- 0022-3042
- 1471-4159
- Cited by
- 76
- References
- 16
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Structure/function of α‐synuclein in health and disease: rational development of animal models for Parkinson's and related diseases. https://app.cochat.ai/papers/10.1046/j.1471-4159.2002.01020.x
- The paper
- Kahle, P. J., Haass, C., Kretzschmar, H. A., & Neumann, M. (2002). Structure/function of α‐synuclein in health and disease: rational development of animal models for Parkinson's and related diseases. Journal of Neurochemistry. https://doi.org/10.1046/j.1471-4159.2002.01020.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.